To obtain the three-dimensional culture from differentiated primary cells and cell lines, a specific extracellular matrix is often used in the lab. An extract from mouse tumours is required for this purpose. This is obtained by implanting sarcoma tumours, which can be up to 20 percent of the mouse’s total body weight by the time the animal is killed to remove the tissue and prepare it for three-dimensional cell cultivation. This has been regarded as the standard method for years, partly because the extract hugely accelerates the growth of any cells. Ethical considerations aside, one disadvantage is the culture’s “unpredictability” due to the highly complex and partly unknown composition of the extracellular matrix, which can also vary from batch to batch. Furthermore, animal matrix components are not always suitable for a human cell culture.

Synthetic hydrogel offers a solution

Cellendes GmbH, which is based in the STERN BioRegion, set about resolving this problem 15 years ago. Biologists Dr. Brigitte Angres and Dr. Helmut Wurst developed
what was then a completely new kind of synthetic hydrogel that meets all research requirements for three-dimensional cell cultivation. It is fully synthetic, clearly defined and completely neutral – and it eliminates any ethical concerns, too. However, it also forces researchers to adopt a new mindset. They need to understand what the cells in their specific project require so as to create the relevant cultivation stimuli that will ensure these cells behave in the desired way. Biomimetic factors such as the gel’s stiffness can be varied at will to achieve this. For this purpose, Cellendes offers a platform with a variety of modules and cell-attracting motifs, meaning any researcher can create their own “personal” cell culture.

The gels are to be used as a biomimetic extracellular matrix in 3D bioprinting and in innovative, complex in vitro models (organ-on-chip) for drug development and personalised medicine. For instance, very fine structures are to be produced to form special barriers on the chips. The NMI will evaluate these properties, the application potential of the newly developed hydrogels and their use as bioinks for 3D bioprinting. In this project, too, the ultimate objective is to create tissue models that meet the 3R goals – replacement, reduction and refinement. Alternative or complementary methods are to be used as a substitute for animal testing wherever possible (replacement), experiments and the number of laboratory animals used in these are to be strictly minimised (reduction), and the suffering, pain and stress experienced by the animals involved in such testing must be kept to an absolute minimum (refinement).

“Bureaucracy is a killer for small companies”

Cellendes hydrogels are therefore extremely significant in terms of medical progress and take increased ethical requirements into account. Although the biotech company is receiving enquiries from all over the world, customers are not queuing up just yet. In 2022, Cellendes relocated to new premises at the Tübingen-Reutlingen Technology Park (TTR) and now has its own laboratory, with all the expense that involves. “Bureaucracy is a killer for small companies,” complains Dr. Wurst. And Cellendes
isn’t even working in the medical sector yet, but still exclusively in research. “Turning research products into pharmaceutical products is extremely costly,” explains Dr. Wurst. Nonetheless, medical applications based on Cellendes hydrogel technology do already exist. TETEC AG in Reutlingen is combining the hydrogels with autologous chondrocytes to regenerate damaged cartilage in joints such as knees.

Dr. Angres and Dr. Wurst have achieved a great deal over the past 15 years. They have launched a unique product that has the potential to transform basic research as well as pharmaceutical and medical research and development work. It can naturally do a lot more than spare countless mice a great deal of suffering. Unfortunately, however, the two biologists have also been forced to acknowledge that a paradigm shift of this kind takes time. It is necessary to prove over and over again that the process is suitable for replacing conventional solutions. The trial results obtained using extracts from mouse tumours and those based on the new hydrogels also need to be comparable. Despite the bureaucratic challenges and financial constraints, the Cellendes founders have never regretted setting up their own business. “We enjoy being our own boss,” emphasises Dr. Wurst.

https://www.cellendes.com/
https://b-brighter.eu/
https://www.nmi.de/en/projects/projektdetail/fobiogel-1